桑戈研究所的一项研究查明了结肠癌、肺癌和Ewing sarrcoma癌症中助长抗药性的四类突变。 A Sanger Institute study identifies four categories of mutations contributing to drug resistance in colon, lung, and Ewing sarcoma cancers.
Wellcome Sanger研究所和合作者进行的一项研究查明了四种类型的突变,这些突变助长结肠癌、肺癌和Ewing sarrcoma癌症的抗药性。 A study by the Wellcome Sanger Institute and collaborators has identified four categories of mutations that contribute to drug resistance in colon, lung, and Ewing sarcoma cancers. 其中包括耐药性突变、吸毒上瘾变异、驱动变异和药物敏感性变异。 These include canonical drug resistance mutations, drug addiction mutations, driver mutations, and drug sensitizing variants. 这项研究成果发表在"自然遗传学"杂志上,旨在指导个性化治疗,并为治疗策略提供信息,从而有可能导致更有效的癌症治疗,从而绕过抗药性. The findings, published in Nature Genetics, aim to guide personalized therapies and inform treatment strategies, potentially leading to more effective cancer treatments that circumvent resistance.